Reuters logo
BRIEF-Summit highlights DMD biomarker phase 2 clinical trial data in presentations at 22nd WMS Congress
October 4, 2017 / 11:12 AM / 2 months ago

BRIEF-Summit highlights DMD biomarker phase 2 clinical trial data in presentations at 22nd WMS Congress

Oct 4 (Reuters) - Summit Therapeutics Plc:

* Summit highlights DMD biomarker validation data and phase 2 clinical trial baseline characteristics in presentations at 22nd WMS Congress

* Summit highlights DMD biomarker validation data and phase 2 clinical trial baseline characteristics in presentations at 22nd WMS congress

* Summit Therapeutics Plc - ‍expect to report first 24-week biopsy, MRI and functional data from phaseout DMD in Q1 2018​

* Summit Therapeutics Plc - ‍top-line data from complete 48-week clinical trial expected in Q3 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below